SCHEMBL3975481

SCHEMBL3975481

Clc1nc(CCCCc2ccccc2)nc2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
MAPT P10636 1/20 0.44
APP P05067 2/20 0.44
MAOB P27338 2/20 0.43
ABCB1 P08183 1/20 0.42
MAOA P21397 2/20 0.41
ADORA2A P29274 1/20 0.41
ADORA2B P29275 1/20 0.41
ADORA1 P30542 1/20 0.41
METAP1 P53582 1/20 0.41
CYP1A2 P05177 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP2D6 P10635 2/20 0.40
LMNA P02545 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
AR P10275 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28224409 0.90 L3MBTL1 (0.49) L3MBTL1MEN1KMT2AMAPTAPP
SCHEMBL16404343 0.86 MAOA (0.50) L3MBTL1MEN1KMT2AMAPTAPP
SCHEMBL790531 0.85 MAPT (0.47) L3MBTL1MAPTLMNAPDE4APDE4B
SCHEMBL7835433 0.83 PDE4A (0.49) L3MBTL1MEN1KMT2AMAPTCYP1A2
SCHEMBL5029528 0.81 PIK3CD (0.49) L3MBTL1MAPTMAOBADORA2AADORA2B
SCHEMBL9173175 0.79 ALDH1A1 (0.55) L3MBTL1MEN1KMT2AMAPTMAOB
SCHEMBL4602308 0.78 MAPT (0.49) L3MBTL1MEN1KMT2AMAPTAPP
SCHEMBL92745 0.77 KMT2A (0.50) L3MBTL1MEN1KMT2AMAPTAPP
SCHEMBL4603760 0.77 L3MBTL1 (0.46) L3MBTL1MEN1KMT2AMAPTAPP
SCHEMBL20595389 0.76 MAPT (0.51) L3MBTL1MEN1KMT2AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547702-B2 4-amino-quinazolines ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2009-06-16 US disclosed
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents ORTHO-MCNEIL PHARMACEUTICALS, INC. 2006-01-26 US disclosed
WO-2004030672-A1 USE OF 4 AMINO-QUINAZOLINES AS ANTI CANCER AGENTS MERCK PATENT GMBH (DE) 2004-04-15 WO disclosed
CN-1474815-A 4-amino-quinazolines Ĭ��ר���ɷ����޹�˾ 2004-02-11 CN disclosed
EP-1318984-A1 4-AMINO-QUINAZOLINES MERCK PATENT GmbH (DE) 2003-06-18 EP disclosed
WO-2002024667-A1 4-AMINO-QUINAZOLINES MERCK PATENT GMBH (DE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents SERPINA3, APOL1, MGAT3 L3MBTL1 2154/4885MEN1 3915/4885KMT2A 4812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.